when was semaglutide fda approved U.S. | The FDA has a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight FDA approves once-a-week diabetes shot

Formulary decisions can be made on clinical and net-cost grounds without a competing revenue motive

By enhancing the bodys natural satiety signals and improving metabolic function, tirzepatide helps patients feel full faster, curb cravings, and lose weight more effectively

Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes

Some protocols use Klows GHK-Cu component to help offset this rather than as a standalone growth strategy

In total, 12 trials from SMART-C were assessed, with the analysis cohort restricted to trials exclusively enrolling participants with diabetes, and participants with diabetes enrolled in the following heart failure and chronic kidney disease trials: DAPA-CKD, EMPA-KIDNEY, DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER